TY - JOUR
T1 - Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care
AU - Mullens, W.
AU - Auricchio, A.
AU - Martens, P.
AU - Witte, K.
AU - Cowie, M.R.
AU - Delgado, V.
AU - Dickstein, K.
AU - Linde, C.
AU - Vernooy, K.
AU - Leyva, F.
AU - Bauersachs, J.
AU - Israel, C.W.
AU - Lund, L.H.
AU - Donal, E.
AU - Boriani, G.
AU - Jaarsma, T.
AU - Berruezo, A.
AU - Traykov, V.
AU - Yousef, Z.
AU - Kalarus, Z.
AU - Nielsen, J.C.
AU - Steffel, J.
AU - Vardas, P.
AU - Coats, A.
AU - Seferovic, P.
AU - Edvardsen, T.
AU - Heidbuchel, H.
AU - Ruschitzka, F.
AU - Leclercq, C.
AU - European Society of Cardiology
N1 - Publisher Copyright:
© 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway.
AB - Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway.
KW - Cardiac resynchronization therapy
KW - Response
KW - Heart failure
KW - Implementation
KW - Utilization
KW - Care pathways
KW - Disease modification
KW - Disease management
KW - Outcome
KW - HEART-FAILURE PATIENTS
KW - IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
KW - PERMANENT ATRIAL-FIBRILLATION
KW - EXPERT CONSENSUS STATEMENT
KW - REDUCED EJECTION FRACTION
KW - NONSUSTAINED VENTRICULAR-TACHYCARDIA
KW - ATRIOVENTRICULAR JUNCTION ABLATION
KW - ANGIOTENSIN-NEPRILYSIN INHIBITION
KW - BUNDLE-BRANCH BLOCK
KW - LONG-TERM OUTCOMES
U2 - 10.1093/europace/euaa411
DO - 10.1093/europace/euaa411
M3 - Article
C2 - 34037728
SN - 1099-5129
VL - 23
SP - 1324
EP - 1342
JO - EP Europace
JF - EP Europace
IS - 8
ER -